Logo

American Heart Association

  56
  0


Final ID: MP1229

Post-Impella Creatinine as a Predictor of Length of Stay Outcomes in Patients Undergoing Heart Transplant After Impella 5.5 Support

Abstract Body (Do not enter title and authors here): Background: Renal dysfunction is a known prognostic factor in advanced heart failure and among patients receiving temporary mechanical circulatory support (tMCS). However, the predictive value of post-Impella creatinine in determining healthcare resource utilization in patients bridged to transplant with Impella 5.5 remains unclear. This study aimed to evaluate the association between post-Impella creatinine and key hospitalization metrics in this population.

Methods: We performed a retrospective cohort study of patients who received Impella 5.5 as a bridge-to-transplant between January 2020 and January 2025. Serum creatinine was collected 72 hours after Impella placement. The primary outcome was device-to-discharge time. Secondary outcomes included transplant-to-discharge time, post-transplant ICU length of stay (LOS), and total LOS (admission-discharge). Univariate and multivariable linear regressions were used to examine the association between post-Impella creatinine and each outcome, adjusting for age, gender, BMI, and LVEF.

Results: 133 patients were supported with the Impella 5.5 as BTT and were included (median age 58 years (51–65), 82.7% were male, and 71.4% presented with non-ischemic cardiomyopathy. The median BMI was 27.7 (24.3–32.3), LVEF 17% (15–22), and post-Impella creatinine 1.32 mg/dL (0.96–1.71). The median device-to-discharge time was 45 days (29-64), transplant-to-discharge time was 14 days (12–19), ICU LOS post-transplant was 6 days (4–8), and total LOS was 58 days (42–76). Higher post-Impella creatinine was significantly associated with longer device-to-discharge time (β = 6.67, p = 0.004), longer transplant-to-discharge duration (β = 3.42 p = 0.003), longer ICU LOS (β = 2.19, p = 0.007), and longer total LOS (β = 7.24, p = 0.002) on univariate analysis. Post-impella creatinine remained significantly associated with device-to-discharge time in the multivariate model after adjusting for confounders (β = 6.33, p = 0.006). Importantly, this suggests that patients with lower post-Impella creatinine levels may experience shorter hospitalizations and faster recovery trajectories following transplant.

Conclusions: Post-Impella creatinine is a significant predictor of prolonged hospitalization in patients supported with Impella 5.5 as a bridge to transplant. These findings emphasize the prognostic importance of early renal function assessment and may guide risk stratification and resource planning in advanced heart failure care.
  • Mautong, Hans  ( John H. Stroger Jr. Hospital , Chicago , Illinois , United States )
  • Chaudhary, Sanjay  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Goswami, Rohan  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Desai, Aarti  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Alak, çetin  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Wlodkowski, Peter  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Ruiz, Jose  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Leoni, Juan  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Nativi-nicolau, Jose  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Patel, Parag  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Shapiro, Anna  ( Mayo Clinic , Jacksonville , Florida , United States )
  • Author Disclosures:
    Hans Mautong: DO NOT have relevant financial relationships | Sanjay Chaudhary: DO NOT have relevant financial relationships | Rohan Goswami: No Answer | Aarti Desai: DO NOT have relevant financial relationships | çetin alak: DO NOT have relevant financial relationships | Peter Wlodkowski: DO NOT have relevant financial relationships | Jose Ruiz: DO NOT have relevant financial relationships | Juan Leoni: DO NOT have relevant financial relationships | Jose Nativi-Nicolau: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alnylam:Active (exists now) ; Research Funding (PI or named investigator):Natera:Active (exists now) ; Research Funding (PI or named investigator):Alexion:Active (exists now) | Parag Patel: DO NOT have relevant financial relationships | Anna Shapiro: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Pushing the Limits: ECMO, Impella, and the Science Behind Their Power

Sunday, 11/09/2025 , 09:15AM - 10:15AM

Moderated Digital Poster Session

More abstracts on this topic:
Artificial intelligence-driven morbidity prediction in acute kidney injury after acute type A aortic dissection surgery

Zhu Zhihui, Chen Zheyuan, Liu Nan, Lai Yongqiang

A Heart Transplant Patient’s Mysterious Illness: A Diagnostic Odyssey

Alkalbani Mutaz, Nayer Hassan, Cochrane Adam, Saeed Ibrahim, Psotka Mitchell, Rollins Allman, Kennedy Jamie, Blumer Vanessa

More abstracts from these authors:
Variation in Impella 5.5 Support Duration and Ischemic Time Across Donor Transport Technologies

Dadwal Surbhi, Desai Aarti, Ruiz Jose, Shapiro Anna, Goswami Rohan

Support duration as a prognostic indicator in temporary MCS: divergent outcomes based on the 14-day FDA approved duration

Desai Aarti, Patel Parag, Goswami Rohan, Mautong Hans, Dadwal Surbhi, Wlodkowski Peter, Ruiz Jose, Yip Daniel, Lyle Melissa, Leoni Juan, Nativi-nicolau Jose

You have to be authorized to contact abstract author. Please, Login
Not Available